New medication for itching in liver disease
Part of Digestive system clinical trials.
This study tests a new medication called nemolizumab to see if it can reduce the intense itching caused by certain liver diseases (PBS or PSC). The drug may help block a protein that triggers itch signals, offering relief for people whose current treatments haven't worked well.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have primary biliary sclerosis (PBS) or primary sclerosing cholangitis (PSC), which are types of liver disease that can cause long-term itching.
- You must have had itching for at least 6 months.
- Your itching must be moderate to severe — for example, a score of 5 or higher on a 0–10 scale.
- Your liver disease should be stable, without recent major complications like fluid build-up in the belly, confusion from liver problems, or bleeding from veins in the throat or stomach.
- You must not have advanced liver failure or be waiting for a liver transplant, and you cannot be pregnant or planning to become pregnant during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug called TH104 to see if it can reduce itching in people with primary biliary cholangitis. The study will help find out if TH104 is safe and effective for this symptom.
This study tests a new medication called nemolizumab for people with lichen planopilaris (LPP), a type of scarring hair loss. It aims to see if the drug can help reduce scalp itching and improve the condition.
This study continues to test an experimental medicine (linerixibat) for itching caused by primary biliary cholangitis (PBC). It's for people who have already been in a prior study of this medicine and may help keep itching under control.
This study looks at how well nemolizumab works in real-world settings for adults with moderate-to-severe prurigo nodularis, a skin condition that causes intense itching and bumps. If you are starting this medication as part of your normal care, you may be able to join.
This study looks at itching caused by drug-induced liver injury. Researchers want to understand who gets itchy and how bad it is, which could help improve care for people with this condition.
This study tests a new injectable medicine (nemolizumab) for people with moderate-to-severe eczema that hasn't been helped enough by topical treatments. It aims to reduce itching and skin symptoms. The trial will compare the drug to a placebo in Chinese participants.
Hear when a new Cholestatic Liver Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.